NGF and Alzheimer disease: This exploratory study is the first to report a correlation between the cholinergic marker ChAT in CSF and EEG oscillations in the alpha and theta frequency range during encapsulated NGF delivery to patients with a definite AD diagnosis as confirmed by a cortical biopsy (Eriksdotter-Jönhagen et al., 2012).